Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von A van Ommen-Nijhof und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Thiotepa. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Dutch Cancer Society.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands.
- Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of internal medicine, St Antonius hospital, Nieuwegein, the Netherlands.
- Department of radiotherapy, NKI-AVL, Amsterdam, the Netherlands.
- Department of biometrics, NKI-AVL, Amsterdam, the Netherlands.
- Department of internal medicine, Rijnstate, Arnhem, the Netherlands.
- Department of internal medicine, Ziekenhuisgroep Twente, Almelo, Hengelo, the Netherlands.
Förderung
- Dutch Cancer Society
Zitieren
APA
van Ommen-Nijhof, A., Steenbruggen, T. G., Wiersma, T. G., Balduzzi, S., Daletzakis, A., Holtkamp, M. J., Delfos, M., Schot, M., Beelen, K., Siemerink, E. J. M., Heijns, J., Mandjes, I. A., Wesseling, J., Rosenberg, E. H., Vrancken Peeters, M. J. T., Linn, S. C., & Sonke, G. S. (2024). Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115083
Vancouver
van Ommen-Nijhof A, Steenbruggen TG, Wiersma TG, Balduzzi S, Daletzakis A, Holtkamp MJ, et al. Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115083
BibTeX
@article{vanOmmenNijhof2024,
author = {van Ommen-Nijhof, A and Steenbruggen, T G and Wiersma, T G and Balduzzi, S and Daletzakis, A and Holtkamp, M J and Delfos, M and Schot, M and Beelen, K and Siemerink, E J M and Heijns, J and Mandjes, I A and Wesseling, J and Rosenberg, E H and Vrancken Peeters, M J T and Linn, S C and Sonke, G S},
title = {Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115083}
}
EUVIMED